| Year |
Citation |
Score |
| 2015 |
Quesseveur G, Portal B, Basile JA, Ezan P, Mathou A, Halley H, Leloup C, Fioramonti X, Déglon N, Giaume C, Rampon C, Guiard BP. Attenuated Levels of Hippocampal Connexin 43 and its Phosphorylation Correlate with Antidepressant- and Anxiolytic-Like Activities in Mice. Frontiers in Cellular Neuroscience. 9: 490. PMID 26733815 DOI: 10.3389/Fncel.2015.00490 |
0.654 |
|
| 2015 |
Zemdegs J, Quesseveur G, Jarriault D, Pénicaud L, Fioramonti X, Guiard BP. High fat diet-induced metabolic disorders impairs serotonergic function and anxiety-like behaviours in mice. British Journal of Pharmacology. PMID 26472268 DOI: 10.1111/Bph.13343 |
0.603 |
|
| 2015 |
Hache G, Guiard BP, Nguyen TH, Quesseveur G, Gardier AM, Peters D, Munro G, Coudoré F. Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain. European Journal of Pain (London, England). 19: 322-33. PMID 25045036 DOI: 10.1002/Ejp.550 |
0.654 |
|
| 2014 |
Petit AC, Quesseveur G, Gressier F, Colle R, David DJ, Gardier AM, Ferreri F, Lépine JP, Falissard B, Verstuyft C, Guiard BP, Corruble E. Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 54: 76-82. PMID 24801750 DOI: 10.1016/J.Pnpbp.2014.04.013 |
0.679 |
|
| 2013 |
Quesseveur G, Gardier AM, Guiard BP. The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs. Current Drug Targets. 14: 1277-94. PMID 24020973 DOI: 10.2174/13894501113149990209 |
0.709 |
|
| 2013 |
Quesseveur G, David DJ, Gaillard MC, Pla P, Wu MV, Nguyen HT, Nicolas V, Auregan G, David I, Dranovsky A, Hantraye P, Hen R, Gardier AM, Déglon N, Guiard BP. BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Translational Psychiatry. 3: e253. PMID 23632457 DOI: 10.1038/Tp.2013.30 |
0.693 |
|
| 2013 |
Quesseveur G, Repérant C, David DJ, Gardier AM, Sanchez C, Guiard BP. 5-HT₂A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system. Experimental Brain Research. 226: 285-95. PMID 23411676 DOI: 10.1007/S00221-013-3434-3 |
0.731 |
|
| 2013 |
Nguyen HT, Guiard BP, Bacq A, David DJ, David I, Quesseveur G, Gautron S, Sanchez C, Gardier AM. Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice. British Journal of Pharmacology. 168: 103-16. PMID 22233336 DOI: 10.1111/J.1476-5381.2012.01850.X |
0.692 |
|
| 2013 |
Quesseveur G, Petit A, Gressier F, Colle R, David D, Gardier A, Verstuyft C, Sanchez C, Corruble E, Guiard B. S.12.07 Role of 5-HT1A/5-HT2A receptors interaction in the severity of depression and antidepressant response European Neuropsychopharmacology. 23: S131. DOI: 10.1016/S0924-977X(13)70173-1 |
0.62 |
|
| 2013 |
Quesseveur G, Petit A, Gressier F, Colle R, David D, Gardier A, Verstuyft C, Corruble E, Guiard B. P.1.019 Role of the 5-HT2A receptor in the mechanism of action of antidepressant drugs: a translational human–mouse study European Neuropsychopharmacology. 23: S18-S19. DOI: 10.1016/S0924-977X(13)70021-X |
0.57 |
|
| 2013 |
Petit A, Quesseveur G, Gressier F, Verstuyft C, Guiard B, Corruble E. Association entre polymorphismes du gène du récepteur 2A à la sérotonine et trouble dépressif majeur unipolaire, une étude translationnelle European Psychiatry. 28: 31-32. DOI: 10.1016/J.Eurpsy.2013.09.077 |
0.465 |
|
| 2012 |
Quesseveur G, Nguyen HT, Gardier AM, Guiard BP. 5-HT2 ligands in the treatment of anxiety and depression. Expert Opinion On Investigational Drugs. 21: 1701-25. PMID 22917059 DOI: 10.1517/13543784.2012.719872 |
0.724 |
|
| 2012 |
Rainer Q, Nguyen HT, Quesseveur G, Gardier AM, David DJ, Guiard BP. Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration. Molecular Pharmacology. 81: 106-12. PMID 22031471 DOI: 10.1124/Mol.111.075796 |
0.723 |
|
| Show low-probability matches. |
